Clinical hematology international最新文献_第2页

Allogeneic hematopoietic stem cell transplantation for VEXAS syndrome: A review and a case report. 异基因造血干细胞移植治疗VEXAS综合征：回顾并附一例报告。

Clinical hematology international Pub Date : 2026-05-26 eCollection Date: 2026-01-01 DOI: 10.46989/001c.161719

Kentaro Nagae, Hiroyuki Muranushi, Yasuhito Nannya, Takeshi Maeda

{"title":"Allogeneic hematopoietic stem cell transplantation for VEXAS syndrome: A review and a case report.","authors":"Kentaro Nagae, Hiroyuki Muranushi, Yasuhito Nannya, Takeshi Maeda","doi":"10.46989/001c.161719","DOIUrl":"10.46989/001c.161719","url":null,"abstract":"Background: VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome is caused by somatic UBA1 mutations and frequently complicated by myelodysplastic syndrome (MDS). Conventional immunosuppressive and anti-inflammatory therapies are often ineffective, and allogeneic hematopoietic stem cell transplantation (allo-HSCT) is currently the only curative treatment, although its optimal timing and donor selection remain uncertain.Case presentation: A 67-year-old man with VEXAS syndrome and MDS harboring UBA1 (p.M41T) and EZH2 mutations, refractory to azacitidine and corticosteroids, successfully underwent allo-HSCT from a one-antigen-mismatched related donor. Post-transplant chronic graft-versus-host disease was well controlled with ruxolitinib.Methods and results: We reviewed eight studies comprising 45 allo-HSCT recipients with VEXAS syndrome. The median age at transplantation was 59 years, and patients had received a median of five prior systemic therapies. MDS was present in 53.3% of cases, while 42.2% underwent transplantation for VEXAS without overt hematologic malignancy. The most frequent UBA1 variant was p.Met41Val (37.8%). At last follow-up, 84.4% of patients were alive, with resolution of inflammatory manifestations in most cases.Conclusion: Allo-HSCT represents a curative option for refractory VEXAS syndrome. Comprehensive genetic profiling may aid in identifying candidates for early transplantation. If early transplantation is required, human leukocyte antigen-mismatched donors may be selected.","PeriodicalId":93942,"journal":{"name":"Clinical hematology international","volume":"8 2","pages":"40-49"},"PeriodicalIF":0.0,"publicationDate":"2026-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13218630/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148140129","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Is Pseudo-progression post-CAR T therapy real? car - T治疗后的伪进展是真的吗？

Clinical hematology international Pub Date : 2026-05-12 eCollection Date: 2026-01-01 DOI: 10.46989/001c.160121

Alicia Shin, Kian Rahbari, Wichai Chinratanalab, Bipin Savani, Adetola Kassim, James Jerkins, Bhagirathbhai Dholaria, Lindsay Orton, Rachel Gilmore, Kendall Shultes, Jana Sawyer, Salyka Sengsayadeth, Olalekan Oluwole, Tae Kon Kim

引用次数: 0

Bladder mass following bone marrow transplant for sickle cell disease: A diagnostic dilemma. 镰状细胞病骨髓移植后膀胱肿块：诊断困境。

Clinical hematology international Pub Date : 2026-05-04 eCollection Date: 2026-01-01 DOI: 10.46989/001c.161296

Yusuf Adelabu, Ugonna O Fakile, Wale Q Oladimeji, Kayode Oseni, Moses A Ogunjimi, Titilayo G Bamigboye, Blessing N Aziken-John, Amina Enegbuma, Zainab Olayiwola, Olufunto Kalejaiye, Titilope A Adeyemo, Ann Ogbenna, Karina Wilkerson, Edamisan Temiye, Adeseye M Akinsete, Adetola A Kassim

引用次数: 0

Guidelines and consensus for minimal residual disease-adapted therapy in multiple myeloma from the Pan-Pacific multiple myeloma working group. 泛太平洋多发性骨髓瘤工作组关于多发性骨髓瘤最小残留疾病适应治疗的指南和共识。

Clinical hematology international Pub Date : 2026-05-04 eCollection Date: 2026-01-01 DOI: 10.46989/001c.160933

Wenming Chen, Zhen Cai, Chor Sang Chim, Wee Joo Chng, Juan Du, Chengcheng Fu, Wen Gao, Ichiro Hanamura, Jian Hou, Jeffrey Shang-Yi Huang, Tadao Ishida, Chunrui Li, Aijun Liu, Vadim Ptushkin, Naoki Takezako, Raymond Siu Ming Wong, Dok Hyun Yoon

{"title":"Guidelines and consensus for minimal residual disease-adapted therapy in multiple myeloma from the Pan-Pacific multiple myeloma working group.","authors":"Wenming Chen, Zhen Cai, Chor Sang Chim, Wee Joo Chng, Juan Du, Chengcheng Fu, Wen Gao, Ichiro Hanamura, Jian Hou, Jeffrey Shang-Yi Huang, Tadao Ishida, Chunrui Li, Aijun Liu, Vadim Ptushkin, Naoki Takezako, Raymond Siu Ming Wong, Dok Hyun Yoon","doi":"10.46989/001c.160933","DOIUrl":"10.46989/001c.160933","url":null,"abstract":"Treatment of multiple myeloma (MM) has entered the era of deep remission-oriented therapy, where minimal residual disease (MRD) has become a key indicator for treatment response and long-term prognosis, surpassing conventional complete remission criteria. However, the optimal integration of MRD into clinical decision-making remains to be established. This expert consensus offers evidence-based guidance on redefining treatment goals in the era of CD38-based therapy, incorporating MRD status into therapeutic decisions, standardizing MRD detection, and integrating new technologies to address current challenges. The consensus supports including MRD assessment in treatment evaluation for almost all MM patients and recommends a comprehensive approach that combines bone marrow, imaging, and peripheral blood-based assessments. For patients receiving CD38-based therapy, achieving and sustaining MRD negativity is strongly linked to improved outcomes. The timing and frequency of MRD testing should be adapted to treatment phases, and CD38-based therapy may be used as part of active maintenance strategies, especially in high-risk populations. Dynamic MRD monitoring is emphasized as a critical part of disease management. Both next-generation flow and next-generation sequencing are considered interchangeable for prognostic assessment, while peripheral residual disease detection is a promising direction for future disease surveillance. This consensus provides a practical framework for integrating MRD assessment into MM clinical management. Dynamic, MRD-guided treatment strategies may enable more precise risk stratification and personalized therapy, ultimately improving long-term patient outcomes.","PeriodicalId":93942,"journal":{"name":"Clinical hematology international","volume":"8 2","pages":"7-25"},"PeriodicalIF":0.0,"publicationDate":"2026-05-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13148062/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147847103","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Should monitoring guidelines and decision to treat for I⁠gM MGUS be different when caring for Jehovah's Witness patients? 在照顾耶和华见证会病人时，监测指南和治疗I - gM MGUS的决定是否应有所不同？

Clinical hematology international Pub Date : 2026-04-23 eCollection Date: 2026-01-01 DOI: 10.46989/001c.158440

Marshall Rosenberg, Alisha P Maity, Karthik Shankar, Caroline Dunne, Arezoo Ghaneie

{"title":"Should monitoring guidelines and decision to treat for I⁠gM MGUS be different when caring for Jehovah's Witness patients?","authors":"Marshall Rosenberg, Alisha P Maity, Karthik Shankar, Caroline Dunne, Arezoo Ghaneie","doi":"10.46989/001c.158440","DOIUrl":"10.46989/001c.158440","url":null,"abstract":"A practicing Jehovah's Witness with diagnosed IgM monoclonal gammopathy of undetermined significance (MGUS) in 2014 was hospitalized within one year of her annual checkup. She had hyperviscosity syndrome with blurry vision and severe anemia but, due to religious beliefs, would not accept blood products. She was treated with therapeutic plasma exchange therapy with subjective improvement of her blurry vision, decrease in her serum viscosity, and improvement of her anemia. This bloodless medicine patient (BMP) had annual follow up per the Mayo Clinic Stratification System guidelines for her asymptomatic MGUS, as she fell into the intermediate-risk category given her age, laboratory values, and lack of symptoms. Due to the inability to provide proper rescue therapy with blood products in the event of anemia, we suggest adjusting the monitoring and surveillance interval for BMPs regardless of laboratory values. We suggest that BMPs undergo additional monitoring including iron and coagulation studies to preempt and prevent potential complications of symptomatic anemia, coagulopathy, and hyperviscosity syndrome. We recommend shortening the follow-up for these patients to every 3-6 months, as opposed to the standard follow-up that is recommended for IgM MGUS (typically ranging from 6-12 months). This would also drive earlier conversations about the risks and benefits of initiating earlier treatment in these patients, given their risks of complications if their MGUS progresses to malignancy.","PeriodicalId":93942,"journal":{"name":"Clinical hematology international","volume":"8 2","pages":"1-6"},"PeriodicalIF":0.0,"publicationDate":"2026-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13109894/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147792246","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Disseminated adenovirus infection following CAR T-cell therapy: Early-onset presentation in a patient with relapsed refractory mantle cell lymphoma. CAR - t细胞治疗后播散性腺病毒感染：复发难治性套细胞淋巴瘤患者的早发性表现。

Clinical hematology international Pub Date : 2026-03-30 eCollection Date: 2026-01-01 DOI: 10.46989/001c.157628

Anusha Gopalam, Noha Soror, Aqsa Ashraf, Emily Siegrist, Joseph Sassine, Taha Al-Juhaishi

引用次数: 0

Leukemia cutis and all-trans retinoic acid-induced myocarditis in acute promyelocytic leukemia. 急性早幼粒细胞白血病的皮肤白血病和全反式维甲酸诱导的心肌炎。

Clinical hematology international Pub Date : 2026-03-26 eCollection Date: 2026-01-01 DOI: 10.46989/001c.158170

Kian J Rahbari, Parth C Patel, Sarah Profitt, Justin T Kelley, Katie A O'Connell, Anna K Dewan, Kathryn E Kennedy, Erica E Mittlebeeler, Ashwin Kishtagari, Somedeb Ball, Sanjay R Mohan, Kateryna Fedorov

引用次数: 0

MajesTEC-3: Redefining what's possible in multiple myeloma. MajesTEC-3：重新定义多发性骨髓瘤的可能性。

Clinical hematology international Pub Date : 2026-03-12 eCollection Date: 2026-01-01 DOI: 10.46989/001c.158751

Samer Al Hadidi, Mahmoud Gaballa

引用次数: 0

Co-occurrence of angioimmunoblastic T-cell lymphoma and aggressive-refractory plasma-cell neoplasm: Two new cases and literature review. 血管免疫母细胞t细胞淋巴瘤与侵袭性难治性浆细胞肿瘤共发2例并文献复习。

Clinical hematology international Pub Date : 2026-03-11 eCollection Date: 2026-01-01 DOI: 10.46989/001c.158183

M Christina Cox, Claudia Seimonte, Erica Giacobbi, Gianmario Pasqualone, Livio Pupo, Annagiulia Zizzari, Luca Franceschini, Adriano Venditti, Massimiliano Postorino

{"title":"Co-occurrence of angioimmunoblastic T-cell lymphoma and aggressive-refractory plasma-cell neoplasm: Two new cases and literature review.","authors":"M Christina Cox, Claudia Seimonte, Erica Giacobbi, Gianmario Pasqualone, Livio Pupo, Annagiulia Zizzari, Luca Franceschini, Adriano Venditti, Massimiliano Postorino","doi":"10.46989/001c.158183","DOIUrl":"10.46989/001c.158183","url":null,"abstract":"Angioimmunoblastic T-cell lymphoma (AITL) is a rare and aggressive peripheral T-cell lymphoma of T-follicular helper (TFH) cell origin, characterized by systemic manifestations, immune dysregulation, and frequent secondary B-cell proliferations. While Epstein-Barr virus (EBV)-related diffuse large B-cell lymphoma develops in up to 20% of AITL cases, the occurrence of overt plasma cell neoplasms such as multiple myeloma (MM) has been documented only in isolated reports. We describe two new patients with AITL complicated by highly aggressive, treatment-refractory plasma-cell neoplasia, including the first documented case of primary cutaneous myeloma, and provide a comprehensive review of all published cases of concurrent systemic T-cell lymphoma (TCL) and plasma-cell neoplasm. A systematic search of PubMed, Web of Science, and Google Scholar identified 16 previously reported cases, yielding a total of 18 patients. These included several TCL subtypes. In most cases, the plasma-cell neoplasm occurred synchronously or shortly after TCL diagnosis. Approximately 50% of patients had an IgA paraprotein. Overall outcomes were dismal, with a median survival of less than two months following diagnosis of the second malignancy. EBV was detected in neoplastic plasma cells in only a minority of cases, suggesting alternative pathogenetic mechanisms such as cytokine-driven B-cell activation or shared clonal origin.","PeriodicalId":93942,"journal":{"name":"Clinical hematology international","volume":"8 1","pages":"49-55"},"PeriodicalIF":0.0,"publicationDate":"2026-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12991438/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147476661","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Chronic graft versus host disease in upper limb: Calling upper limb rehabilitation specialists for improving outcomes in patients. 上肢慢性移植物抗宿主病：呼吁上肢康复专家改善患者的预后。

Clinical hematology international Pub Date : 2026-03-11 eCollection Date: 2026-01-01 DOI: 10.46989/001c.158500

Jaleel A Mohammed, Caroline Couthard, Ahmed AlGhamdi, Collins Ogbeivor, Shahrukh K Hashmi

{"title":"Chronic graft versus host disease in upper limb: Calling upper limb rehabilitation specialists for improving outcomes in patients.","authors":"Jaleel A Mohammed, Caroline Couthard, Ahmed AlGhamdi, Collins Ogbeivor, Shahrukh K Hashmi","doi":"10.46989/001c.158500","DOIUrl":"10.46989/001c.158500","url":null,"abstract":"Background: Chronic graft versus host disease (cGVHD) is a complex post-transplant complication resulting in varying degrees of musculoskeletal (MSK) manifestations, including sclerosis-type skin conditions, fasciitis, and osteopenia, avascular necrosis affecting the shoulder, elbow and hands apart from other joints of the body. A large proportion of these can often miss out on the expertise of upper limb therapists.Study objectives: This paper aims to outline upper limb cGVHD manifestations to raise awareness among upper limb physiotherapists and rehabilitation specialists, so that patients can receive more focused, optimal care.Methods: An electronic search was conducted across a wide database covering the period from 1990 to 2025. Further manual search used Google Scholar to help identify relevant articles. Boolean operators 'AND' and 'OR' combined keywords such as chronic graft versus host disease, acute graft versus host disease, allogenic hematopoietic stem cell transplantation, hematopoietic cell transplantation, stem cell transplant, bone marrow transplant, physiotherapy, upper limb specialist, musculoskeletal, fasciitis, and scleroderma.Results: A total of 4,393 titles were screened against the pre-set inclusion and exclusion criteria, and only 3 articles were found to be suitable for this narrative review. All 3 articles were case studies of upper limb cGVHD and rehabilitation reporting positive outcomes on patients' upper and lower limb range of motion, function, and quality of life (QoL).Conclusion: cGVHD can cause various MSK issues, especially in the upper limbs. It is important to collaborate with upper limb physiotherapy and occupational therapy experts to improve awareness and patient outcomes.","PeriodicalId":93942,"journal":{"name":"Clinical hematology international","volume":"8 1","pages":"37-48"},"PeriodicalIF":0.0,"publicationDate":"2026-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12982154/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147464402","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0